University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Douglas Goodin

Douglas Goodin, M.D.

Medical director, Multiple Sclerosis Center

Dr. Douglas Goodin, director of the Multiple Sclerosis Center at UCSF Medical Center, is a neurologist and an internationally renowned expert in the treatment and research of multiple sclerosis.. He earned a bachelor of sciences degree in genetics and biochemistry at the University of Washington in Seattle; a master of sciences degree in molecular biology at Purdue University in Indiana; and a medical degree from the University of California, Irvine. He completed a residency in neurology at UCSF where he joined the medical center staff in 1982. In addition to multiple sclerosis, Goodin's research interests include various forms of dementia. Goodin also is a professor of neurology at UCSF.

Conditions & Treatments

Clinics

Multiple Sclerosis Center
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

More about Douglas Goodin

Education

University of California, Irvine 1978

Residencies

UCSF, Neurology 1982

Selected Research and Publications

  1. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, Desimone TM, Knappertz V. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNß-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22.
  2. Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL. Evidence-based guideline update: Intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society. Neurology. 2012 Feb 21; 78(8):585-9.
  3. Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL. Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials*. J Clin Neurophysiol. 2012 Feb; 29(1):101-8.
  4. Marcus JF, Shalev SM, Harris CA, Goodin DS, Josephson SA. Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution. Arch Neurol. 2012 Jan; 69(1):129-32.
  5. Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7.
  6. Patsopoulos NA. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
  7. Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V. Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. PLoS One. 2011; 6(11):e22444.
  8. Goodin DS. Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous road. Mult Scler. 2011 Nov; 17(11):1274-5.
  9. Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012 Feb; 18(2):181-95.
  10. Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V. Interferon ß-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011 Apr 5; 76(14):1222-8.
  11. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011; 6(2):e16664.
  12. Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, Pelletier D. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011 Feb 22; 76(8):686-92.
  13. Goodin DS. The genetic basis of multiple sclerosis: a model for MS susceptibility. BMC Neurol. 2010; 10:101.
  14. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug; 68(2):145-50.
  15. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
  16. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 8; 74(23):1877-85.
  17. Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009 Oct; 15(10):1175-82.
  18. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97.
  19. Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36.
  20. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology. 2009 May 19; 72(20):1760-5.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California